• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

区分严重急性呼吸综合征冠状病毒2感染与疫苗接种后的抗体反应：流行病学研究面临的挑战

Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses Between Infection and Vaccination: Challenges for Epidemiological Research.

作者信息

Nayagam Sunav N, Coote William, Carroll Matthew T C, Toh Zheng Quan, Licciardi Paul V, Abramson Michael J, Walker-Bone Karen, Lane Tyler J

机构信息

School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

Monash Rural Health Churchill, Monash University, Churchill, Victoria, Australia.

出版信息

J Infect Dis. 2025 Jul 30;232(1):9-13. doi: 10.1093/infdis/jiaf295.

DOI:10.1093/infdis/jiaf295
PMID:40459240
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12308668/
Abstract

Some common coronavirus disease 2019 (COVID-19) vaccines elicit antibody responses that most serological tests are unable to differentiate from an infection response. This presents a challenge for COVID-19 epidemiology and serosurveys. In this perspective, we examine the potential scale of this problem.

摘要

一些常见的2019冠状病毒病（COVID-19）疫苗引发的抗体反应，大多数血清学检测无法将其与感染反应区分开来。这给COVID-19流行病学和血清学调查带来了挑战。从这个角度出发，我们研究了这个问题可能的规模。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a059/12308668/ffef13976663/jiaf295f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a059/12308668/d24fbcf22bea/jiaf295f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a059/12308668/ffef13976663/jiaf295f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a059/12308668/d24fbcf22bea/jiaf295f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a059/12308668/ffef13976663/jiaf295f2.jpg

相似文献

1
Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses Between Infection and Vaccination: Challenges for Epidemiological Research.区分严重急性呼吸综合征冠状病毒2感染与疫苗接种后的抗体反应：流行病学研究面临的挑战
J Infect Dis. 2025 Jul 30;232(1):9-13. doi: 10.1093/infdis/jiaf295.
2
Antibody tests for identification of current and past infection with SARS-CoV-2.抗体检测用于鉴定 SARS-CoV-2 的现症感染和既往感染。
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.
3
Dynamic monitoring of antibody titers in people living with HIV during Omicron epidemic: comparison between unvaccinated and vaccinated individuals.奥密克戎疫情期间HIV感染者抗体滴度的动态监测：未接种疫苗者与接种疫苗者的比较
BMC Infect Dis. 2025 Jul 30;25(1):962. doi: 10.1186/s12879-025-11387-3.
4
Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.哥伦比亚对新冠病毒疫苗接种特异性抗体反应的纵向随访
J Med Virol. 2025 Jan;97(1):e70133. doi: 10.1002/jmv.70133.
5
Anti-SARS-CoV-2 total immunoglobulin and neutralising antibody responses in healthy blood donors throughout the COVID-19 pandemic: a longitudinal observational study.在整个 COVID-19 大流行期间健康献血者的抗 SARS-CoV-2 总免疫球蛋白和中和抗体反应：一项纵向观察研究。
Swiss Med Wkly. 2024 Jul 1;154:3408. doi: 10.57187/s.3408.
6
Individuals Infected with SARS-CoV-2 Prior to COVID-19 Vaccination Maintain Vaccine-Induced RBD-Specific Antibody Levels and Viral Neutralization Activity for One Year.在接种新冠疫苗之前感染过新冠病毒的个体，其疫苗诱导的RBD特异性抗体水平和病毒中和活性可维持一年。
Viruses. 2025 Apr 29;17(5):640. doi: 10.3390/v17050640.
7
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.针对 COVID-19 的一种改良信使核糖核酸-脂质纳米颗粒候选疫苗的安全性和免疫原性：一项 1 期、剂量递增研究的结果。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2408863. doi: 10.1080/21645515.2024.2408863. Epub 2024 Oct 18.
8
Establishment of human post-vaccination SARS-CoV-2 standard reference sera.建立人接种 SARS-CoV-2 疫苗后标准参考血清。
J Immunol Methods. 2024 Jul;530:113698. doi: 10.1016/j.jim.2024.113698. Epub 2024 May 31.
9
Heterotypic immunity from prior SARS-CoV-2 infection but not COVID-19 vaccination associates with lower endemic coronavirus incidence.先前 SARS-CoV-2 感染产生的异源免疫，但不是 COVID-19 疫苗接种，与较低的地方性冠状病毒发病率相关。
Sci Transl Med. 2024 Jun 12;16(751):eado7588. doi: 10.1126/scitranslmed.ado7588.
10
Repeated COVID-19 mRNA-based vaccination contributes to SARS-CoV-2 neutralizing antibody responses in the mucosa.重复接种基于 mRNA 的 COVID-19 疫苗可增强黏膜中的 SARS-CoV-2 中和抗体应答。
Sci Transl Med. 2024 Oct 23;16(770):eadn2364. doi: 10.1126/scitranslmed.adn2364.

本文引用的文献

1
Seroprevalence trends of anti-SARS-CoV-2 antibodies in the adult population of the São Paulo Municipality, Brazil: Results from seven serosurveys from June 2020 to April 2022. The SoroEpi MSP Study.巴西圣保罗市成年人中抗 SARS-CoV-2 抗体的血清流行率趋势：2020 年 6 月至 2022 年 4 月进行的七项血清学调查结果。SoroEpi MSP 研究。
PLoS One. 2024 Aug 26;19(8):e0309441. doi: 10.1371/journal.pone.0309441. eCollection 2024.
2
Early warning COVID-19 outbreak in long-term care facilities using wastewater surveillance: correlation, prediction, and interaction with clinical and serological statuses.利用废水监测对长期护理设施中 COVID-19 爆发进行早期预警：相关性、预测以及与临床和血清学状态的相互作用。
Lancet Microbe. 2024 Oct;5(10):100894. doi: 10.1016/S2666-5247(24)00126-5. Epub 2024 Aug 22.
3
SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020-2023.2020-2023 年期间纽约市 COVID-19 大流行多个波次的 SARS-CoV-2 血清学调查。
Nat Commun. 2024 Jul 11;15(1):5847. doi: 10.1038/s41467-024-50052-2.
4
Tracking the evolution of anti-SARS-CoV-2 antibodies and long-term humoral immunity within 2 years after COVID-19 infection.追踪 COVID-19 感染后 2 年内抗 SARS-CoV-2 抗体和长期体液免疫的演变。
Sci Rep. 2024 Jun 11;14(1):13417. doi: 10.1038/s41598-024-64414-9.
5
Serological assays for differentiating natural COVID-19 infection from vaccine induced immunity.用于区分自然感染新冠病毒与疫苗诱导免疫的血清学检测
J Clin Virol. 2024 Feb;170:105621. doi: 10.1016/j.jcv.2023.105621. Epub 2023 Dec 1.
6
Distinguishing SARS-CoV-2 infection and vaccine responses up to 18 months post-infection using nucleocapsid protein and receptor-binding domain antibodies.使用核衣壳蛋白和受体结合域抗体区分感染后长达18个月的新冠病毒感染和疫苗反应。
Microbiol Spectr. 2023 Sep 22;11(5):e0179623. doi: 10.1128/spectrum.01796-23.
7
Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection.冠状病毒刺突蛋白中保守区域对研发抗SARS-CoV-2感染新型疫苗的意义
Vaccines (Basel). 2023 Feb 24;11(3):545. doi: 10.3390/vaccines11030545.
8
Pathogenesis and Mechanisms of SARS-CoV-2 Infection in the Intestine, Liver, and Pancreas.SARS-CoV-2 在肠道、肝脏和胰腺中的感染发病机制和机制。
Cells. 2023 Jan 9;12(2):262. doi: 10.3390/cells12020262.
9
SARS-CoV-2 Spike Protein Vaccine-Induced Immune Imprinting Reduces Nucleocapsid Protein Antibody Response in SARS-CoV-2 Infection.SARS-CoV-2 刺突蛋白疫苗诱导的免疫印迹降低了 SARS-CoV-2 感染中的核衣壳蛋白抗体反应。
J Immunol Res. 2022 Jul 29;2022:8287087. doi: 10.1155/2022/8287087. eCollection 2022.
10
T Cells Targeting SARS-CoV-2: By Infection, Vaccination, and Against Future Variants.靶向严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的T细胞：通过感染、疫苗接种以及针对未来变体
Front Med (Lausanne). 2021 Dec 24;8:793102. doi: 10.3389/fmed.2021.793102. eCollection 2021.